VYNE Therapeutics
VYNE
58 hedge funds and large institutions have $110M invested in VYNE Therapeutics in 2019 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 30 increasing their positions, 12 reducing their positions, and 4 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 12
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
0.01% more ownership
Funds ownership: 1.06% → 1.06% (+0.01%)
2% less funds holding
Funds holding: 59 → 58 (-1)
21% less capital invested
Capital invested by funds: $139M → $110M (-$29.4M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$2.01M |
| 2 |
BlackRock
New York
|
+$1.94M |
| 3 |
State Street
Boston,
Massachusetts
|
+$522K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$445K |
| 5 |
Renaissance Technologies
New York
|
+$430K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.22M |
| 2 |
SIM
Spark Investment Management
New York
|
-$394K |
| 3 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$352K |
| 4 |
Morgan Stanley
New York
|
-$242K |
| 5 |
First Manhattan
New York
|
-$211K |
VYNE Hedge Fund Activity: Q2 2019 in Review
58 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q2 2019, worth a combined $110M — down 21% from $139M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VYNE positions and 4 closed out — a net gain of 1 holder — while 30 added to existing stakes and 12 trimmed.
The largest buyer was Mangrove Partners, adding an estimated $2.01M. The largest seller was Great Point Partners, cutting an estimated $2.22M.
- 58 institutional investors held VYNE Therapeutics (VYNE) as of Q2 2019, down from 59 in Q1 2019.
- Funds reported $110M of VYNE Therapeutics stock for Q2 2019, down 21% quarter-over-quarter.
- 5 funds opened new VYNE Therapeutics positions in Q2 2019 and 4 closed out, a net change of +1 holder.
- The largest VYNE Therapeutics buyer in Q2 2019 was Mangrove Partners, an estimated $2.01M added.
- The largest VYNE Therapeutics seller in Q2 2019 was Great Point Partners, an estimated $2.22M sold.
Based on aggregated 13F filings for Q2 2019.